Perspective Therapeutics (NYSE:CATX) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of Perspective Therapeutics (NYSE:CATX) to a strong-buy rating in a research note released on Thursday morning,Zacks.com reports.

A number of other equities research analysts have also recently commented on CATX. Royal Bank of Canada reissued an “outperform” rating and set a $16.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Wedbush restated an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research note on Friday, January 24th. Oppenheimer lowered their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, November 22nd. Finally, Scotiabank initiated coverage on shares of Perspective Therapeutics in a research note on Friday. They issued a “sector outperform” rating and a $15.00 target price for the company. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $15.13.

Perspective Therapeutics Stock Down 3.3 %

Perspective Therapeutics stock opened at $2.61 on Thursday. The firm’s fifty day moving average price is $3.21 and its 200-day moving average price is $7.71. Perspective Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $19.05.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC raised its holdings in shares of Perspective Therapeutics by 3,994.9% in the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after buying an additional 5,370,392 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Perspective Therapeutics by 8.0% during the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock worth $64,014,000 after purchasing an additional 355,685 shares during the last quarter. Deerfield Management Company L.P. Series C raised its holdings in shares of Perspective Therapeutics by 4.3% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company’s stock worth $9,375,000 after purchasing an additional 120,991 shares during the last quarter. Octagon Capital Advisors LP raised its holdings in shares of Perspective Therapeutics by 62.1% during the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock worth $7,352,000 after purchasing an additional 882,528 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of Perspective Therapeutics by 119.6% during the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after purchasing an additional 1,192,812 shares during the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.